Trial Profile

A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Oct 2021 According to a Rhythm media release, results of post-hoc analyses presented at the Obesity Medicine Association's Overcoming Obesity 2021 Conference and its Digital Experience (DX).
14 Oct 2021 Results of post-hoc analyses published in the Rhythm Media Release.
23 Jul 2021 According to a Rhythm Pharmaceuticals media release, the European Commission (EC) has granted marketing authorization to IMCIVREE (setmelanotide) in the European Union (EU) for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com